This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Binford, S. L.
Right arrow Articles by Patick, A. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Binford, S. L.
Right arrow Articles by Patick, A. K.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2007, p. 4366-4373, Vol. 51, No. 12
0066-4804/07/$08.00+0     doi:10.1128/AAC.00905-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

In Vitro Resistance Study of Rupintrivir, a Novel Inhibitor of Human Rhinovirus 3C Protease{triangledown}

S. L. Binford, P. T. Weady, F. Maldonado, M. A. Brothers, D. A. Matthews, and A. K. Patick*

Pfizer Global Research and Development, San Diego, California 92121

Received 10 July 2007/ Returned for modification 3 September 2007/ Accepted 17 September 2007

Rupintrivir (formerly AG7088) is an irreversible inhibitor of the human rhinovirus (HRV) 3C protease that has been demonstrated to have in vitro activity against all HRVs tested, consistent with its interaction with a strictly conserved subset of amino acids in the 3C protease. The potential for resistance was studied following in vitro serial passage of HRV serotypes 14, 2, 39, and Hanks in the presence of increasing rupintrivir concentrations. HRV variants with reduced susceptibilities to rupintrivir (sevenfold for HRV 14) or with no significant reductions in susceptibility but genotypic changes (HRV 2, 39, and Hanks) were initially isolated following 14 to 40 cumulative days in culture (three to six passages). Sequence analysis of the 3C protease identified one to three substitutions in diverse patterns but with common features (T129T/A, T131T/A, and T143P/S in HRV 14; N165T in HRV 2; N130N/K and L136L/F in HRV 39; T130A in HRV Hanks). Notably, three of the four HRV variants contained a substitution at residue 130 (residue 129 in HRV 14). Continued selection in the presence of escalating concentrations of rupintrivir (40 to 72 days) resulted in the accumulation of additional mutations (A121A/V and Y139Y/H in HRV 14, E3E/G and A103A/V in HRV 2, S105T in HRV 39), with only minimal further reductions in susceptibility (up to fivefold). The ability of specific substitutions to confer resistance was examined by susceptibility testing of HRV 14 variants constructed to contain 3C protease mutations. In summary, the slow accumulation of multiple amino acid substitutions with only minimal to moderate reductions in susceptibility highlight the advantages of 3C protease as an antiviral target.

* Corresponding author. Mailing address: Department of Virology, Pfizer Global Research and Development, 10777 Science Center Drive, San Diego, CA 92121. Phone: (858) 622-3117. Fax: (858) 678-8182. E-mail: amy.patick{at}pfizer.com

{triangledown} Published ahead of print on 1 October 2007.

Antimicrobial Agents and Chemotherapy, December 2007, p. 4366-4373, Vol. 51, No. 12
0066-4804/07/$08.00+0     doi:10.1128/AAC.00905-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Tsai, M.-T., Cheng, Y.-H., Liu, Y.-N., Liao, N.-C., Lu, W.-W., Kung, S.-H. (2009). Real-Time Monitoring of Human Enterovirus (HEV)-Infected Cells and Anti-HEV 3C Protease Potency by Fluorescence Resonance Energy Transfer. Antimicrob. Agents Chemother. 53: 748-755 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»